Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Ion Genomics With Andrew P. Han

Posts by and about Ion Genomics With Andrew P. Han

16 posts

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · 1d

    Illumina Tops AI Cell Challenge, but Models Struggle to Predict Biology

    Corporate teams dominated the leaderboard this year, with teams from Xaira Therapeutics, Novo Nordisk, and South Korea’s AgingLab placing in the top six.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · 3d

    Illumina Appeals to MRD Testers With Duplex Sequencing: Newsletter, Nov. 18

    Google drops AlphaGenome 2, Illumina layoffs, 10x Genomics inks more global clinical research collabs, Ansa Bio raises $71.5M Series C, Twist Bio’s Fiscal Q4, and more.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · 3d

    Ansa Biotechnologies Raises $71.5M Series C Round for Enzymatic DNA Synthesis

    Ansa bio has raised $211 million to date and said it quadrupled manufacturing capacity in the past year.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · 5d

    10x Genomics Inks Single-Cell Autoimmune Research Collabs in Germany, South Korea

    The German study will follow 750 patients with rheumatic diseases while the South Korean study will look at response to JAK inhibitors in alopecia areata.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 13

    Twist Bio Holds AI-Driven 2027 Outlook at $100M Despite 175 Percent Growth in FY26

    The synthetic biology company hit $126.6M in revenue in its fiscal fourth quarter, with AI drug discovery as its fastest-growing segment.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 11

    Natera Faces Lawsuits After Baylor Genetics Data Breach: Newsletter, Nov. 11

    Ion Genomics @AMP, Natera’s New CEO, Guardant adds epigenetics apps to Liquid 360, lots of Q3 results, MyOme licenses methylation signatures, and more.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 10

    GeneDx Q3 Revenue Rises 5 Percent as Other Panels Business Continues to Erode

    Exome and genome test volume grew 25 percent year over year but the company trimmed its full-year exome growth outlook.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 10

    Natera Signatera to Guide Enrollment and Serve as Endpoint in Incyte Colorectal Cancer Trial

    The study will enroll stage II and III colorectal cancer patients who test MRD-positive after surgery and chemotherapy.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 6

    Grail Misses Revenue Estimates as Marketing Costs Surge: Q3 Earnings Roundup

    Also: Qiagen, Sophia Genetics, BillionToOne report financial results and links to Guardant Health, Natera, 10x Genomics, Pacific Biosciences, Tempus AI.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 6

    Guardant's Shield Test Hits 83K Tests in Q3, Driving 36 Percent Jump in Revenue

    Guardant Health raised its full-year revenue outlook to as much as $1.37 billion after Shield colorectal cancer screening test volume more than tripled.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 6

    Natera Appoints New CEO, Makes Mystery $30M Acquisition

    Natera's oncology business drove quarterly revenue to $794 million and prompted a $140 million increase to full-year guidance.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 5

    10x Genomics Preps for Atera Era Even as Spatial Instrument Revenue Dips

    The single-cell and spatial technology company reported marginal revenue growth in the third quarter and raised its full-year revenue outlook.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 5

    PacBio Reusable Consumables Sales Grow, Enabling Project Wins in Q3

    Instrument revenue was up in Q3, while consumables revenue slipped and the company tightened its full-year revenue outlook.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 4

    10x's Anthropic Partnership Yields New Single-Cell Analysis Software: Newsletter, Nov. 4

    Illumina CEO says it’s ‘not about just selling sequencers’ on Q3 call, 10x Sues Waters in Europe, Ultima gets first PopSeq win, a TCR study from BioNTech and Tempus AI, and more.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 4

    Illumina, Ultima Win Roles in Singaporean 450K-Person Genomics Study

    The project is Phase III of Singapore's National Precision Medicine program and builds on PRECISE-SG100K.

    Read on Substack

  • via Substack
    Ion Genomics With Andrew P. Han
    Podcast · Nov 4

    Tempus AI Q3 Revenue Jumps 23 Percent Driven by Oncology Testing

    Oncology revenue was $172.6 million, up 28 percent year over year while data & applications revenue was up 33 percent to $108.1 million.

    Read on Substack